Vimarsana
Biggest News Aggregation in the World

Page 10 - Topline News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Topline. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Topline Today - Breaking & Trending Today

FOXNEWS Fox News Tonight June 4, 2024 05:14:00 - Vimarsana News

FOXNEWS Fox News Tonight June 4, 2024 05:14:00

>> well, i mean, it's interesting politically. i mean, what biodynamicsg tical, is essentially he inherited a growing economy from donald trump. s iswe were coming out of the pandemic, you know, in fits and starts, but coming outgrowin economy, everything was opening up. >> and then he spent a craploa d of money and then he helped cause inflation. he reappointed a fedhe chair tht kept the gas on with low interest rates and printing money and then you got what you have today, which is, yes, an economy that's the topline. >> numbers are all good. he's right. bunumbert why does the why are s the ...

INVENTIVA: Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD - Vimarsana News

INVENTIVA: Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD

Lanifibranor 800mg achieved the primary efficacy endpoint demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy (1H-MRS) following 24 weeks of treatment in patients

DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis - Vimarsana News

DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

Topline data anticipated in Q4 2023 CUPERTINO, Calif., June 7, 2023 /PRNewswire/ -- DURECT Corporation , a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ... | June 7, 2023

FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy - Vimarsana News

FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

Study did not meet the primary endpointPamrevlumab was generally safe and well tolerated Topline results from LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with DMD expected 3Q 2023 ... | June 7, 2023

SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial - Vimarsana News

SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial

Topline results using the Company's SCI-110 met the trial’s primary and secondary end points, demonstrating high safety profile and reduced agitationTel-Aviv, June 02, 2023 -- SciSparc Ltd. ,... | June 2, 2023